Last 12 months
Inside the activity.
0 purchase rows · 0 sale rows
Disclosed non-derivative P/S rows, by transaction month. Includes amendments and private transactions.Monthly counts
| Month | Purchases | Sales |
|---|---|---|
| Nov 2025 | 0 | 0 |
| Dec 2025 | 0 | 0 |
| Jan 2026 | 0 | 0 |
| Feb 2026 | 0 | 0 |
| Mar 2026 | 0 | 0 |
| Apr 2026 | 0 | 0 |
| May 2026 | 0 | 0 |
| Jun 2026 | 0 | 0 |
| Jul 2026 | 0 | 0 |
| Aug 2026 | 0 | 0 |
| Sep 2026 | 0 | 0 |
| Oct 2026 | 0 | 0 |
Latest available
Insider transactions
Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Owner / reported role | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| February 28, 2024 Filed Feb 28, 2024 22:30 UTC |
Nielsen JackDirector
|
GrantStock Option (Right to Buy) · Derivative | 4,411 | $0.00 Strike: $0.96 | $0.00 |
DisclosureSEC source: 0001610717-24-000096 · form4.xml · derivative · entry 2 Nielsen Jack · CIK 0001602402 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 4,411 Underlying: Common Stock · 4,411 shares Expires 2031-06-17 F1 · price: On February 27, 2024, the issuer canceled, pursuant to the issuer's option exchange program, an option for 15,000 of the issuer's shares granted to the reporting person on June 17, 2021. In exchange, on February 28, 2024, the reporting person received a replacement option, for 4,411 shares, having an exercise price of $0.96 per share. F2 · derivative.exercise_date: The shares subject to the option will vest and become exercisable on the one year anniversary of the date of grant, subject to the reporting person's continued service with the issuer through such one year anniversary. Read SEC document |
| February 28, 2024 Filed Feb 28, 2024 22:29 UTC |
Nuechterlein CaroleDirector
|
GrantStock Option (Right to Buy) · Derivative | 4,411 | $0.00 Strike: $0.96 | $0.00 |
DisclosureSEC source: 0001610717-24-000095 · form4.xml · derivative · entry 2 Nuechterlein Carole · CIK 0001665133 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 4,411 Underlying: Common Stock · 4,411 shares Expires 2031-06-17 F1 · price: On February 27, 2024, the issuer canceled, pursuant to the issuer's option exchange program, an option for 15,000 of the issuer's shares granted to the reporting person on June 17, 2021. In exchange, on February 28, 2024, the reporting person received a replacement option, for 4,411 shares, having an exercise price of $0.96 per share. F2 · derivative.exercise_date: The shares subject to the option will vest and become exercisable on the one year anniversary of the date of grant, subject to the reporting person's continued service with the issuer through such one year anniversary. Read SEC document |
| February 28, 2024 Filed Feb 28, 2024 22:29 UTC |
Martell Bridget ADirector
|
GrantStock Option (Right to Buy) · Derivative | 8,823 | $0.00 Strike: $0.96 | $0.00 |
DisclosureSEC source: 0001610717-24-000094 · form4.xml · derivative · entry 2 Martell Bridget A · CIK 0001629627 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 8,823 Underlying: Common Stock · 8,823 shares Expires 2031-11-16 F1 · price: On February 27, 2024, the issuer canceled, pursuant to the issuer's option exchange program, an option for 30,000 of the issuer's shares granted to the reporting person on November 16, 2021. In exchange, on February 28, 2024, the reporting person received a replacement option, for 8,823 shares, having an exercise price of $0.96 per share. F2 · derivative.exercise_date: The shares subject to the option will vest and become exercisable on the one year anniversary of the date of grant, subject to the reporting person's continued service with the issuer through such one year anniversary. Read SEC document |
| February 27, 2024 Filed Feb 28, 2024 17:33 UTC |
McClure Matthew W.Chief Medical Officer
|
Disposition to issuerStock Option (Right to Buy) · Derivative | 23,000 | $0.00 Strike: $3.06 | $0.00 |
DisclosureSEC source: 0001610717-24-000100 · form4.xml · derivative · entry 3 McClure Matthew W. · CIK 0001927121 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 23,000 shares Expires 2032-02-04 F3 · price: On February 27, 2024, the issuer canceled, pursuant to the issuer's option exchange program, an option for 23,000 of the issuer's shares granted to the reporting person on February 4, 2022. In exchange, on February 28, 2024, the reporting person received a replacement option, for 16,428 shares, having an exercise price of $0.96 per share. Read SEC document |
| February 27, 2024 Filed Feb 28, 2024 17:33 UTC |
McClure Matthew W.Chief Medical Officer
|
Disposition to issuerStock Option (Right to Buy) · Derivative | 92,000 | $0.00 Strike: $3.06 | $0.00 |
DisclosureSEC source: 0001610717-24-000100 · form4.xml · derivative · entry 2 McClure Matthew W. · CIK 0001927121 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 92,000 shares Expires 2032-02-04 F2 · price: On February 27, 2024, the issuer canceled, pursuant to the issuer's option exchange program, an option for 92,000 of the issuer's shares granted to the reporting person on February 4, 2022. In exchange, on February 28, 2024, the reporting person received a replacement option, for 65,713 shares, having an exercise price of $0.96 per share. Read SEC document |
| February 27, 2024 Filed Feb 28, 2024 17:33 UTC |
McClure Matthew W.Chief Medical Officer
|
Disposition to issuerStock Option (Right to Buy) · Derivative | 255,626 | $0.00 Strike: $16.18 | $0.00 |
DisclosureSEC source: 0001610717-24-000100 · form4.xml · derivative · entry 1 McClure Matthew W. · CIK 0001927121 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 255,626 shares Expires 2030-12-01 F1 · price: On February 27, 2024, the issuer canceled, pursuant to the issuer's option exchange program, an option for 255,626 of the issuer's shares granted to the reporting person on December 1, 2020. In exchange, on February 28, 2024, the reporting person received a replacement option, for 75,183 shares, having an exercise price of $0.96 per share. Read SEC document |
| February 27, 2024 Filed Feb 28, 2024 22:35 UTC |
Hirth PeterDirector
|
Disposition to issuerStock Option (Right to Buy) · Derivative | 15,000 | $0.00 Strike: $26.58 | $0.00 |
DisclosureSEC source: 0001610717-24-000102 · form4.xml · derivative · entry 1 Hirth Peter · CIK 0001813780 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 15,000 shares Expires 2031-06-17 F1 · price: On February 27, 2024, the issuer canceled, pursuant to the issuer's option exchange program, an option for 15,000 of the issuer's shares granted to the reporting person on June 17, 2021. In exchange, on February 28, 2024, the reporting person received a replacement option, for 4,411 shares, having an exercise price of $0.96 per share. Read SEC document |
| February 27, 2024 Filed Feb 28, 2024 22:34 UTC |
Scopa James PaulDirector
|
Disposition to issuerStock Option (Right to Buy) · Derivative | 30,000 | $0.00 Strike: $29.10 | $0.00 |
DisclosureSEC source: 0001610717-24-000101 · form4.xml · derivative · entry 1 Scopa James Paul · CIK 0001356950 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 30,000 shares Expires 2031-04-26 F1 · price: On February 27, 2024, the issuer canceled, pursuant to the issuer's option exchange program, an option for 30,000 of the issuer's shares granted to the reporting person on April 26, 2021. In exchange, on February 28, 2024, the reporting person received a replacement option, for 8,823 shares, having an exercise price of $0.96 per share. Read SEC document |
| February 27, 2024 Filed Feb 28, 2024 22:32 UTC |
Calhoun Lesley AnnSee Remarks
|
Disposition to issuerStock Option (Right to Buy) · Derivative | 26,250 | $0.00 Strike: $3.06 | $0.00 |
DisclosureSEC source: 0001610717-24-000099 · form4.xml · derivative · entry 3 Calhoun Lesley Ann · CIK 0001730866 · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 26,250 shares Expires 2032-02-04 F3 · price: On February 27, 2024, the issuer canceled, pursuant to the issuer's option exchange program, an option for 26,250 of the issuer's shares granted to the reporting person on February 4, 2022. In exchange, on February 28, 2024, the reporting person received a replacement option, for 18,750 shares, having an exercise price of $0.96 per share. Read SEC document |
| February 27, 2024 Filed Feb 28, 2024 22:32 UTC |
Calhoun Lesley AnnSee Remarks
|
Disposition to issuerStock Option (Right to Buy) · Derivative | 105,000 | $0.00 Strike: $3.06 | $0.00 |
DisclosureSEC source: 0001610717-24-000099 · form4.xml · derivative · entry 2 Calhoun Lesley Ann · CIK 0001730866 · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 105,000 shares Expires 2032-02-04 F2 · price: On February 27, 2024, the issuer canceled, pursuant to the issuer's option exchange program, an option for 105,000 of the issuer's shares granted to the reporting person on February 4, 2022. In exchange, on February 28, 2024, the reporting person received a replacement option, for 74,998 shares, having an exercise price of $0.96 per share. Read SEC document |
| February 27, 2024 Filed Feb 28, 2024 22:32 UTC |
Calhoun Lesley AnnSee Remarks
|
Disposition to issuerStock Option (Right to Buy) · Derivative | 176,237 | $0.00 Strike: $16.18 | $0.00 |
DisclosureSEC source: 0001610717-24-000099 · form4.xml · derivative · entry 1 Calhoun Lesley Ann · CIK 0001730866 · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 176,237 shares Expires 2030-12-01 F1 · price: On February 27, 2024, the issuer canceled, pursuant to the issuer's option exchange program, an option for 176,237 of the issuer's shares granted to the reporting person on December 1, 2020. In exchange, on February 28, 2024, the reporting person received a replacement option, for 51,833 shares, having an exercise price of $0.96 per share. Read SEC document |
| February 27, 2024 Filed Feb 28, 2024 22:32 UTC |
BLATT LAWRENCEDirector · Chief Executive Officer
|
Disposition to issuerStock Option (Right to Buy) · Derivative | 80,850 | $0.00 Strike: $3.06 | $0.00 |
DisclosureSEC source: 0001610717-24-000098 · form4.xml · derivative · entry 3 BLATT LAWRENCE · CIK 0001242110 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 80,850 shares Expires 2032-02-04 F3 · price: On February 27, 2024, the issuer canceled, pursuant to the issuer's option exchange program, an option for 80,850 of the issuer's shares granted to the reporting person on February 4, 2022. In exchange, on February 28, 2024, the reporting person received a replacement option, for 57,749 shares, having an exercise price of $0.96 per share. Read SEC document |
| February 27, 2024 Filed Feb 28, 2024 22:32 UTC |
BLATT LAWRENCEDirector · Chief Executive Officer
|
Disposition to issuerStock Option (Right to Buy) · Derivative | 323,400 | $0.00 Strike: $3.06 | $0.00 |
DisclosureSEC source: 0001610717-24-000098 · form4.xml · derivative · entry 2 BLATT LAWRENCE · CIK 0001242110 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 323,400 shares Expires 2032-02-04 F2 · price: On February 27, 2024, the issuer canceled, pursuant to the issuer's option exchange program, an option for 323,400 of the issuer's shares granted to the reporting person on February 4, 2022. In exchange, on February 28, 2024, the reporting person received a replacement option, for 230,999 shares, having an exercise price of $0.96 per share. Read SEC document |
| February 27, 2024 Filed Feb 28, 2024 22:32 UTC |
BLATT LAWRENCEDirector · Chief Executive Officer
|
Disposition to issuerStock Option (Right to Buy) · Derivative | 450,000 | $0.00 Strike: $16.18 | $0.00 |
DisclosureSEC source: 0001610717-24-000098 · form4.xml · derivative · entry 1 BLATT LAWRENCE · CIK 0001242110 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 450,000 shares Expires 2030-12-01 F1 · price: On February 27, 2024, the issuer canceled, pursuant to the issuer's option exchange program, an option for 450,000 of the issuer's shares granted to the reporting person on December 1, 2020. In exchange, on February 28, 2024, the reporting person received a replacement option, for 132,352 shares, having an exercise price of $0.96 per share. Read SEC document |
| February 27, 2024 Filed Feb 28, 2024 22:31 UTC |
Symons Julian A.See Remarks
|
Disposition to issuerStock Option (Right to Buy) · Derivative | 26,250 | $0.00 Strike: $3.06 | $0.00 |
DisclosureSEC source: 0001610717-24-000097 · form4.xml · derivative · entry 3 Symons Julian A. · CIK 0001824727 · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 26,250 shares Expires 2032-02-04 F3 · price: On February 27, 2024, the issuer canceled, pursuant to the issuer's option exchange program, an option for 26,250 of the issuer's shares granted to the reporting person on February 4, 2022. In exchange, on February 28, 2024, the reporting person received a replacement option, for 18,750 shares, having an exercise price of $0.96 per share. Read SEC document |
| February 27, 2024 Filed Feb 28, 2024 22:31 UTC |
Symons Julian A.See Remarks
|
Disposition to issuerStock Option (Right to Buy) · Derivative | 105,000 | $0.00 Strike: $3.06 | $0.00 |
DisclosureSEC source: 0001610717-24-000097 · form4.xml · derivative · entry 2 Symons Julian A. · CIK 0001824727 · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 105,000 shares Expires 2032-02-04 F2 · price: On February 27, 2024, the issuer canceled, pursuant to the issuer's option exchange program, an option for 105,000 of the issuer's shares granted to the reporting person on February 4, 2022. In exchange, on February 28, 2024, the reporting person received a replacement option, for 74,998 shares, having an exercise price of $0.96 per share. Read SEC document |
| February 27, 2024 Filed Feb 28, 2024 22:31 UTC |
Symons Julian A.See Remarks
|
Disposition to issuerStock Option (Right to Buy) · Derivative | 200,000 | $0.00 Strike: $16.18 | $0.00 |
DisclosureSEC source: 0001610717-24-000097 · form4.xml · derivative · entry 1 Symons Julian A. · CIK 0001824727 · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 200,000 shares Expires 2030-12-01 F1 · price: On February 27, 2024, the issuer canceled, pursuant to the issuer's option exchange program, an option for 200,000 of the issuer's shares granted to the reporting person on December 1, 2020. In exchange, on February 28, 2024, the reporting person received a replacement option, for 58,822 shares, having an exercise price of $0.96 per share. Read SEC document |
| February 27, 2024 Filed Feb 28, 2024 22:30 UTC |
Nielsen JackDirector
|
Disposition to issuerStock Option (Right to Buy) · Derivative | 15,000 | $0.00 Strike: $26.58 | $0.00 |
DisclosureSEC source: 0001610717-24-000096 · form4.xml · derivative · entry 1 Nielsen Jack · CIK 0001602402 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 15,000 shares Expires 2031-06-17 F1 · price: On February 27, 2024, the issuer canceled, pursuant to the issuer's option exchange program, an option for 15,000 of the issuer's shares granted to the reporting person on June 17, 2021. In exchange, on February 28, 2024, the reporting person received a replacement option, for 4,411 shares, having an exercise price of $0.96 per share. Read SEC document |
| February 27, 2024 Filed Feb 28, 2024 22:29 UTC |
Nuechterlein CaroleDirector
|
Disposition to issuerStock Option (Right to Buy) · Derivative | 15,000 | $0.00 Strike: $26.58 | $0.00 |
DisclosureSEC source: 0001610717-24-000095 · form4.xml · derivative · entry 1 Nuechterlein Carole · CIK 0001665133 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 15,000 shares Expires 2031-06-17 F1 · price: On February 27, 2024, the issuer canceled, pursuant to the issuer's option exchange program, an option for 15,000 of the issuer's shares granted to the reporting person on June 17, 2021. In exchange, on February 28, 2024, the reporting person received a replacement option, for 4,411 shares, having an exercise price of $0.96 per share. Read SEC document |
| February 27, 2024 Filed Feb 28, 2024 22:29 UTC |
Martell Bridget ADirector
|
Disposition to issuerStock Option (Right to Buy) · Derivative | 30,000 | $0.00 Strike: $16.52 | $0.00 |
DisclosureSEC source: 0001610717-24-000094 · form4.xml · derivative · entry 1 Martell Bridget A · CIK 0001629627 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 30,000 shares Expires 2031-11-16 F1 · price: On February 27, 2024, the issuer canceled, pursuant to the issuer's option exchange program, an option for 30,000 of the issuer's shares granted to the reporting person on November 16, 2021. In exchange, on February 28, 2024, the reporting person received a replacement option, for 8,823 shares, having an exercise price of $0.96 per share. Read SEC document |
| October 25, 2023 Filed Oct 27, 2023 20:15 UTC |
Nuechterlein CaroleDirector · 10% owner
|
PurchaseWarrant (Right to Buy) · Derivative | 3,966,800 | $0.13 Strike: $0.76 | $495,850.00 |
DisclosureSEC source: 0001610717-23-000320 · form4.xml · derivative · entry 2 Nuechterlein Carole · CIK 0001665133 · Director · 10% owner 10b5-1 filing: No plan indicated Ownership: Indirect · See footnote Disclosed balance after: 3,966,800 Underlying: Common Stock · 3,966,800 shares Expires 2030-10-25 F1 · ownership.nature: Roche Finance Ltd is the direct beneficial owner of these securities of the Issuer. Roche Finance Ltd is a wholly owned subsidiary of Roche Holding Ltd. Roche Holding Ltd is the indirect beneficial owner of these securities of the Issuer. The Reporting Person disclaims beneficial ownership of the securities except to the extent of its pecuniary interest therein, if any. The Reporting Person also disclaims beneficial ownership of any securities of the Issuer that may be or are beneficially owned by any other person or persons other than such Reporting Person. This Form 4 shall not be deemed an admission that any Reporting Person or other person is a beneficial owner of any securities of the Issuer for any purpose, other than the securities reported in this Form 4. Read SEC document |
| October 25, 2023 Filed Oct 27, 2023 20:15 UTC |
Nuechterlein CaroleDirector · 10% owner
|
PurchaseCommon Stock | 7,933,601 | $0.76 | $6,004,149.24 |
DisclosureSEC source: 0001610717-23-000320 · form4.xml · nonDerivative · entry 1 Nuechterlein Carole · CIK 0001665133 · Director · 10% owner 10b5-1 filing: No plan indicated Ownership: Indirect · See footnote Disclosed balance after: 11,025,941 F1 · ownership.nature: Roche Finance Ltd is the direct beneficial owner of these securities of the Issuer. Roche Finance Ltd is a wholly owned subsidiary of Roche Holding Ltd. Roche Holding Ltd is the indirect beneficial owner of these securities of the Issuer. The Reporting Person disclaims beneficial ownership of the securities except to the extent of its pecuniary interest therein, if any. The Reporting Person also disclaims beneficial ownership of any securities of the Issuer that may be or are beneficially owned by any other person or persons other than such Reporting Person. This Form 4 shall not be deemed an admission that any Reporting Person or other person is a beneficial owner of any securities of the Issuer for any purpose, other than the securities reported in this Form 4. Read SEC document |
| October 25, 2023 Filed Oct 27, 2023 20:14 UTC |
BLATT LAWRENCEDirector · Chief Executive Officer
|
GrantWarrants (Right to Buy) · Derivative | 305,138 | $0.13 Strike: $0.76 | $38,142.25 |
DisclosureSEC source: 0001610717-23-000319 · form4.xml · derivative · entry 6 BLATT LAWRENCE · CIK 0001242110 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 305,138 Underlying: Common Stock · 305,138 shares Expires 2030-10-25 Read SEC document |
| October 25, 2023 Filed Oct 27, 2023 20:14 UTC |
BLATT LAWRENCEDirector · Chief Executive Officer
|
GrantCommon Stock | 610,277 | $0.76 | $461,857.63 |
DisclosureSEC source: 0001610717-23-000319 · form4.xml · nonDerivative · entry 1 BLATT LAWRENCE · CIK 0001242110 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,847,575 Read SEC document |
| October 25, 2023 Filed Oct 27, 2023 20:13 UTC |
Scopa James PaulDirector
|
GrantWarrant (Right to Buy) · Derivative | 91,541 | $0.13 Strike: $0.76 | $11,442.63 |
DisclosureSEC source: 0001610717-23-000318 · form4.xml · derivative · entry 2 Scopa James Paul · CIK 0001356950 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 91,541 Underlying: Common Stock · 91,541 shares Expires 2030-10-25 Read SEC document |
| October 25, 2023 Filed Oct 27, 2023 20:13 UTC |
Scopa James PaulDirector
|
GrantCommon Stock | 183,083 | $0.76 | $138,557.21 |
DisclosureSEC source: 0001610717-23-000318 · form4.xml · nonDerivative · entry 1 Scopa James Paul · CIK 0001356950 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 183,083 Read SEC document |
| September 08, 2023 Filed Sep 12, 2023 16:08 UTC |
McClure Matthew W.Chief Medical Officer
|
GrantStock Option (Right to Buy) · Derivative | 48,000 | $0.00 Strike: $0.84 | $0.00 |
DisclosureSEC source: 0001610717-23-000277 · form4.xml · derivative · entry 1 McClure Matthew W. · CIK 0001927121 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 48,000 Underlying: Common Stock · 48,000 shares Expires 2033-09-08 F1 · derivative.exercise_date: 1/48th of the total number of shares vest in forty-eight (48) successive and equal monthly installments measured from July 20, 2023 (the "Vesting Commencement Date"), such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date, subject to the Reporting Person's continued service through each vesting date. Read SEC document |
| September 08, 2023 Filed Sep 12, 2023 20:07 UTC |
Calhoun Lesley AnnSee Remarks
|
GrantStock Option (Right to Buy) · Derivative | 48,000 | $0.00 Strike: $0.84 | $0.00 |
DisclosureSEC source: 0001610717-23-000276 · form4.xml · derivative · entry 1 Calhoun Lesley Ann · CIK 0001730866 · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 48,000 Underlying: Common Stock · 48,000 shares Expires 2033-09-08 F1 · derivative.exercise_date: 1/48th of the total number of shares vest in forty-eight (48) successive and equal monthly installments measured from July 20, 2023 (the "Vesting Commencement Date"), such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date, subject to the Reporting Person's continued service through each vesting date. Read SEC document |
| September 08, 2023 Filed Sep 12, 2023 20:07 UTC |
Quan Lucinda Y.See Remarks
|
GrantStock Option (Right to Buy) · Derivative | 48,000 | $0.00 Strike: $0.84 | $0.00 |
DisclosureSEC source: 0001610717-23-000275 · form4.xml · derivative · entry 1 Quan Lucinda Y. · CIK 0001824711 · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 48,000 Underlying: Common Stock · 48,000 shares Expires 2033-09-08 F1 · derivative.exercise_date: 1/48th of the total number of shares vest in forty-eight (48) successive and equal monthly installments measured from July 20, 2023 (the "Vesting Commencement Date"), such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date, subject to the Reporting Person's continued service through each vesting date. Read SEC document |
| September 08, 2023 Filed Sep 12, 2023 20:06 UTC |
Symons Julian A.See Remarks
|
GrantStock Option (Right to Buy) · Derivative | 48,000 | $0.00 Strike: $0.84 | $0.00 |
DisclosureSEC source: 0001610717-23-000274 · form4.xml · derivative · entry 1 Symons Julian A. · CIK 0001824727 · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 48,000 Underlying: Common Stock · 48,000 shares Expires 2033-09-08 F1 · derivative.exercise_date: 1/48th of the total number of shares vest in forty-eight (48) successive and equal monthly installments measured from July 20, 2023 (the "Vesting Commencement Date"), such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date, subject to the Reporting Person's continued service through each vesting date. Read SEC document |
| September 08, 2023 Filed Sep 12, 2023 20:05 UTC |
BLATT LAWRENCEChief Executive Officer
|
GrantStock Option (Right to Buy) · Derivative | 150,000 | $0.00 Strike: $0.84 | $0.00 |
DisclosureSEC source: 0001610717-23-000273 · form4.xml · derivative · entry 1 BLATT LAWRENCE · CIK 0001242110 · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 150,000 Underlying: Common Stock · 150,000 shares Expires 2033-09-08 F1 · derivative.exercise_date: 1/48th of the total number of shares vest in forty-eight (48) successive and equal monthly installments measured from July 20, 2023 (the "Vesting Commencement Date"), such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date, subject to the Reporting Person's continued service through each vesting date. Read SEC document |
| July 20, 2023 Filed Jul 21, 2023 20:13 UTC |
Hirth PeterDirector
|
GrantStock Option (Right to Buy) · Derivative | 20,000 | $0.00 Strike: $1.00 | $0.00 |
DisclosureSEC source: 0001610717-23-000213 · form4.xml · derivative · entry 1 Hirth Peter · CIK 0001813780 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Stock · 20,000 shares Expires 2033-07-20 F1 · derivative.exercise_date: The shares subject to the option will vest and become exercisable as to 100% of the total number of shares subject to the option on the earlier of the first anniversary of the grant date or immediately prior to the annual meeting in 2024 of the Issuer's stockholders, subject to continuous service to the Issuer through such vesting date. Read SEC document |
| July 20, 2023 Filed Jul 22, 2023 01:06 UTC |
Martell Bridget ADirector
|
GrantStock Option (Right to Buy) · Derivative | 20,000 | $0.00 Strike: $1.00 | $0.00 |
DisclosureSEC source: 0001610717-23-000217 · form4.xml · derivative · entry 1 Martell Bridget A · CIK 0001629627 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Stock · 20,000 shares Expires 2033-07-20 F1 · derivative.exercise_date: The shares subject to the option will vest and become exercisable as to 100% of the total number of shares subject to the option on the earlier of the first anniversary of the grant date or immediately prior to the annual meeting in 2024 of the Issuer's stockholders, subject to continuous service to the Issuer through such vesting date. Read SEC document |
| July 20, 2023 Filed Jul 21, 2023 23:23 UTC |
Nielsen JackDirector
|
GrantStock Option (Right to Buy) · Derivative | 20,000 | $0.00 Strike: $1.00 | $0.00 |
DisclosureSEC source: 0001610717-23-000216 · form4.xml · derivative · entry 1 Nielsen Jack · CIK 0001602402 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Stock · 20,000 shares Expires 2033-07-20 F1 · derivative.exercise_date: The shares subject to the option will vest and become exercisable as to 100% of the total number of shares subject to the option on the earlier of the first anniversary of the grant date or immediately prior to the annual meeting in 2024 of the Issuer's stockholders, subject to continuous service to the Issuer through such vesting date. Read SEC document |
| July 20, 2023 Filed Jul 21, 2023 20:11 UTC |
Scopa James PaulDirector
|
GrantStock Option (Right to Buy) · Derivative | 20,000 | $0.00 Strike: $1.00 | $0.00 |
DisclosureSEC source: 0001610717-23-000212 · form4.xml · derivative · entry 1 Scopa James Paul · CIK 0001356950 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Stock · 20,000 shares Expires 2033-07-20 F1 · derivative.exercise_date: The shares subject to the option will vest and become exercisable as to 100% of the total number of shares subject to the option on the earlier of the first anniversary of the grant date or immediately prior to the annual meeting in 2024 of the Issuer's stockholders, subject to continuous service to the Issuer through such vesting date. Read SEC document |
| July 20, 2023 Filed Jul 21, 2023 20:10 UTC |
Nuechterlein CaroleDirector
|
GrantStock Option (Right to Buy) · Derivative | 20,000 | $0.00 Strike: $1.00 | $0.00 |
DisclosureSEC source: 0001610717-23-000210 · form4.xml · derivative · entry 1 Nuechterlein Carole · CIK 0001665133 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Stock · 20,000 shares Expires 2033-07-20 F1 · derivative.exercise_date: The shares subject to the option will vest and become exercisable as to 100% of the total number of shares subject to the option on the earlier of the first anniversary of the grant date or immediately prior to the annual meeting in 2024 of the Issuer's stockholders, subject to continuous service to the Issuer through such vesting date. Read SEC document |
| March 15, 2023 Filed Mar 17, 2023 16:12 UTC |
McClure Matthew W.Chief Medical Officer
|
GrantStock Option (Right to Buy) · Derivative | 75,000 | $0.00 Strike: $1.34 | $0.00 |
DisclosureSEC source: 0001567619-23-005257 · doc1.xml · derivative · entry 1 McClure Matthew W. · CIK 0001927121 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 75,000 Underlying: Common Stock · 75,000 shares Expires 2033-03-15 F1 · derivative.exercise_date: 1/48th of the total number of shares vest in forty-eight (48) successive and equal monthly installments measured from March 15, 2023 (the "Vesting Commencement Date"), such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date, subject to the Reporting Person's continued service through each vesting date. Read SEC document |
| March 15, 2023 Filed Mar 17, 2023 20:11 UTC |
Symons Julian A.See Remarks
|
GrantStock Option (Right to Buy) · Derivative | 78,750 | $0.00 Strike: $1.34 | $0.00 |
DisclosureSEC source: 0001567619-23-005256 · doc1.xml · derivative · entry 1 Symons Julian A. · CIK 0001824727 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 78,750 Underlying: Common Stock · 78,750 shares Expires 2033-03-15 F1 · derivative.exercise_date: 1/48th of the total number of shares vest in forty-eight (48) successive and equal monthly installments measured from March 15, 2023 (the "Vesting Commencement Date"), such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date, subject to the Reporting Person's continued service through each vesting date. Read SEC document |
| March 15, 2023 Filed Mar 17, 2023 20:11 UTC |
Calhoun Lesley AnnSee Remarks
|
GrantStock Option (Right to Buy) · Derivative | 78,750 | $0.00 Strike: $1.34 | $0.00 |
DisclosureSEC source: 0001567619-23-005255 · doc1.xml · derivative · entry 1 Calhoun Lesley Ann · CIK 0001730866 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 78,750 Underlying: Common Stock · 78,750 shares Expires 2033-03-15 F1 · derivative.exercise_date: 1/48th of the total number of shares vest in forty-eight (48) successive and equal monthly installments measured from March 15, 2023 (the "Vesting Commencement Date"), such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date, subject to the Reporting Person's continued service through each vesting date. Read SEC document |
| March 15, 2023 Filed Mar 17, 2023 20:10 UTC |
Quan Lucinda Y.See Remarks
|
GrantStock Option (Right to Buy) · Derivative | 78,750 | $0.00 Strike: $1.34 | $0.00 |
DisclosureSEC source: 0001567619-23-005254 · doc1.xml · derivative · entry 1 Quan Lucinda Y. · CIK 0001824711 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 78,750 Underlying: Common Stock · 78,750 shares Expires 2033-03-15 F1 · derivative.exercise_date: 1/48th of the total number of shares vest in forty-eight (48) successive and equal monthly installments measured from March 15, 2023 (the "Vesting Commencement Date"), such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date, subject to the Reporting Person's continued service through each vesting date. Read SEC document |
| March 15, 2023 Filed Mar 17, 2023 20:10 UTC |
Beigelman LeonidDirector · President
|
GrantStock Option (Right to Buy) · Derivative | 169,500 | $0.00 Strike: $1.34 | $0.00 |
DisclosureSEC source: 0001567619-23-005252 · doc1.xml · derivative · entry 1 Beigelman Leonid · CIK 0001824721 · Director · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 169,500 Underlying: Common Stock · 169,500 shares Expires 2033-03-15 F1 · derivative.exercise_date: 1/48th of the total number of shares vest in forty-eight (48) successive and equal monthly installments measured from March 15, 2023 (the "Vesting Commencement Date"), such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date, subject to the Reporting Person's continued service through each vesting date. Read SEC document |
| March 15, 2023 Filed Mar 17, 2023 20:09 UTC |
BLATT LAWRENCEChief Executive Officer
|
GrantStock Option (Right to Buy) · Derivative | 242,500 | $0.00 Strike: $1.34 | $0.00 |
DisclosureSEC source: 0001567619-23-005251 · doc1.xml · derivative · entry 1 BLATT LAWRENCE · CIK 0001242110 · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 242,500 Underlying: Common Stock · 242,500 shares Expires 2033-03-15 F1 · derivative.exercise_date: 1/48th of the total number of shares vest in forty-eight (48) successive and equal monthly installments measured from March 15, 2023 (the "Vesting Commencement Date"), such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date, subject to the Reporting Person's continued service through each vesting date. Read SEC document |
| July 07, 2022 Filed Jul 11, 2022 16:15 UTC |
McClure Matthew W.Chief Medical Officer
|
GrantStock Option (Right to Buy) · Derivative | 46,000 | $0.00 Strike: $1.41 | $0.00 |
DisclosureSEC source: 0001567619-22-013870 · doc1.xml · derivative · entry 1 McClure Matthew W. · CIK 0001927121 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 46,000 Underlying: Common Stock · 46,000 shares Expires 2032-07-07 F1 · derivative.exercise_date: 1/48th of the total number of shares vest in forty-eight (48) successive and equal monthly installments measured from July 7, 2022 (the "Vesting Commencement Date"), such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date. Read SEC document |
| July 07, 2022 Filed Jul 11, 2022 20:14 UTC |
Calhoun Lesley AnnSee Remarks
|
GrantStock Option (Right to Buy) · Derivative | 52,500 | $0.00 Strike: $1.41 | $0.00 |
DisclosureSEC source: 0001567619-22-013868 · doc1.xml · derivative · entry 1 Calhoun Lesley Ann · CIK 0001730866 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 52,500 Underlying: Common Stock · 52,500 shares Expires 2032-07-07 F1 · derivative.exercise_date: 1/48th of the total number of shares vest in forty-eight (48) successive and equal monthly installments measured from July 7, 2022 (the "Vesting Commencement Date"), such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date, subject to the Reporting Person's continued service through each vesting date. Read SEC document |
| July 07, 2022 Filed Jul 11, 2022 20:15 UTC |
Quan Lucinda Y.See Remarks
|
GrantStock Option (Right to Buy) · Derivative | 52,500 | $0.00 Strike: $1.41 | $0.00 |
DisclosureSEC source: 0001567619-22-013869 · doc1.xml · derivative · entry 1 Quan Lucinda Y. · CIK 0001824711 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 52,500 Underlying: Common Stock · 52,500 shares Expires 2032-07-07 F1 · derivative.exercise_date: 1/48th of the total number of shares vest in forty-eight (48) successive and equal monthly installments measured from July 7, 2022 (the "Vesting Commencement Date"), such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date, subject to the Reporting Person's continued service through each vesting date. Read SEC document |
| July 07, 2022 Filed Jul 11, 2022 20:13 UTC |
Beigelman LeonidDirector · President
|
GrantStock Option (Right to Buy) · Derivative | 113,000 | $0.00 Strike: $1.41 | $0.00 |
DisclosureSEC source: 0001567619-22-013867 · doc1.xml · derivative · entry 1 Beigelman Leonid · CIK 0001824721 · Director · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 113,000 Underlying: Common Stock · 113,000 shares Expires 2032-07-07 F1 · derivative.exercise_date: 1/48th of the total number of shares vest in forty-eight (48) successive and equal monthly installments measured from July 7, 2022 (the "Vesting Commencement Date"), such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date, subject to the Reporting Person's continued service through each vesting date. Read SEC document |
| July 07, 2022 Filed Jul 11, 2022 20:13 UTC |
BLATT LAWRENCEChief Executive Officer
|
GrantStock Option (Right to Buy) · Derivative | 161,700 | $0.00 Strike: $1.41 | $0.00 |
DisclosureSEC source: 0001567619-22-013866 · doc1.xml · derivative · entry 1 BLATT LAWRENCE · CIK 0001242110 · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 161,700 Underlying: Common Stock · 161,700 shares Expires 2032-07-07 F1 · derivative.exercise_date: 1/48th of the total number of shares vest in forty-eight (48) successive and equal monthly installments measured from July 7, 2022 (the "Vesting Commencement Date"), such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date, subject to the Reporting Person's continued service through each vesting date. Read SEC document |
| July 07, 2022 Filed Jul 11, 2022 20:12 UTC |
Symons Julian A.See Remarks
|
GrantStock Option (Right to Buy) · Derivative | 50,000 | $0.00 Strike: $1.41 | $0.00 |
DisclosureSEC source: 0001567619-22-013865 · doc1.xml · derivative · entry 1 Symons Julian A. · CIK 0001824727 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,000 Underlying: Common Stock · 50,000 shares Expires 2032-07-07 F1 · derivative.exercise_date: 1/48th of the total number of shares vest in forty-eight (48) successive and equal monthly installments measured from July 7, 2022 (the "Vesting Commencement Date"), such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date, subject to the Reporting Person's continued service through each vesting date. Read SEC document |
| June 23, 2022 Filed Jun 27, 2022 20:14 UTC |
Hirth PeterDirector
|
GrantStock Option (Right to Buy) · Derivative | 15,000 | $0.00 Strike: $1.34 | $0.00 |
DisclosureSEC source: 0001567619-22-013391 · doc1.xml · derivative · entry 1 Hirth Peter · CIK 0001813780 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,000 Underlying: Common Stock · 15,000 shares Expires 2032-06-23 F1 · derivative.exercise_date: The shares subject to the option will vest and become exercisable as to 100% of the total number of shares subject to the option on the earlier of the first anniversary of the grant date or immediately prior to the annual meeting in 2023 of the Issuer's stockholders, subject to continuous service to the Issuer through such vesting date. Read SEC document |
| June 23, 2022 Filed Jun 27, 2022 20:14 UTC |
Woiwode ThomasDirector
|
GrantStock Option (Right to Buy) · Derivative | 15,000 | $0.00 Strike: $1.34 | $0.00 |
DisclosureSEC source: 0001567619-22-013392 · doc1.xml · derivative · entry 1 Woiwode Thomas · CIK 0001619294 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,000 Underlying: Common Stock · 15,000 shares Expires 2032-06-23 F1 · derivative.exercise_date: The shares subject to the option will vest and become exercisable as to 100% of the total number of shares subject to the option on the earlier of the first anniversary of the grant date or immediately prior to the annual meeting in 2023 of the Issuer's stockholders, subject to continuous service to the Issuer through such vesting date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.